AmgenCHIX:AMGD 90 10-Year ROIIC % is 1.39 as of Dec. 2025. GuruFocus rates CHIX:AMGD with a GF Score™ of 90/100 and a GF Value™ of €325.97 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 860 Drug Manufacturers companies, Amgen ranks worse than 57.67% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Amgen's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 1.39%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Amgen's 10-Year ROIIC % or its related term are showing as below:
CHIX:AMGd's 10-Year ROIIC % is ranked worse than 57.67% of 860
companies
in the Drug Manufacturers industry
Industry Median: 4.41
vs CHIX:AMGd: 1.39
Amgen (CHIX:AMGd) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Amgen 10-Year ROIIC % Related Terms
Amgen 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Amgen's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMGD vs GILD, PFE, BMY: 10-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Amgen's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen 10-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Amgen's 10-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Amgen (CHIX:AMGD) has a 10-Year ROIIC % of 1.39 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Amgen and its competitors. According to the industry distribution chart, Amgen ranks #496 out of 860 companies in the Drug Manufacturers industry, placing it in the top 57.7%.
Is Amgen's 10-Year ROIIC % too high?
Amgen's current 10-Year ROIIC % is 1.39. The Drug Manufacturers industry median 10-Year ROIIC % is 4.41. Amgen's value of 1.39 is 68.5% below this industry median. Based on the distribution chart, Amgen ranks #496 out of 860 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amgen has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's 10-Year ROIIC % compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #496 out of 860 companies for 10-Year ROIIC %. This places Amgen in the lower half of its industry. The industry median 10-Year ROIIC % is 4.41. Amgen's value of 1.39 is 68.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Drug Manufacturers company?
The median 10-Year ROIIC % among Drug Manufacturers companies is 4.41, based on 860 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current 10-Year ROIIC % of 1.39 is 68.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median 10-Year ROIIC % is 4.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current 10-Year ROIIC % is 1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €325.97, compared to a current price of €285.00 — trading 12.6% below its estimated fair value. The current 10-Year ROIIC % is 1.39 and 68.5% below the Drug Manufacturers industry median of 4.41. Amgen's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current 10-Year ROIIC % is 1.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (CHIX:AMGD) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be undervalued.
The current stock price of €285.00 is trading 12.6% below its estimated GF Value™ of €325.97.
GuruFocus considers Amgen to be Modestly Undervalued.
Key valuation signals for CHIX:AMGD:
10-Year ROIIC %: 1.39
GF Value™: €325.97 vs. price of €285.00 (12.6% below fair value)
Industry Position: 68.5% below the Drug Manufacturers median (#496 of 860)
No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
90GF Score
Get the complete analysis for CHIX:AMGD
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMGD has been successfully added to your 
